Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Home Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

/ Publications

Share the Post

About the Author

AadiSite Support

Related Posts

Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
Read More
Anupam Dalal, MD
Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
Read More
Karin Hehenberger, MD, PhD

Comments

Comments are closed.